Navigation Links
Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
Date:1/1/2014

ussels (symbol: UCB).

Forward-Looking Statements UCB
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations. There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ven
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. NW Bios International Phase III GBM Brain Trial Is Subject Of BBC TV Report In The UK
2. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
3. CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials
4. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
5. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
6. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
7. BioSpecifics Technologies Corp. Announces Initiation of Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome
8. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
9. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
11. Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... The nuclear imaging market is estimated to ... of 12.08%. Nuclear medicine is the use of radioisotopes ... of Nuclear imaging used commonly are PET and SPECT. ... nuclear medicine applications like nuclear cardiology procedures. However, the ... shortage of molybdenum-99 isotope which is in turn will ...
(Date:6/1/2015)... , June 1, 2015 ... weight over large area and improve the quality life ... ulcer. These devices play a significant role in inhibiting ... reduce the need to turn or rotate an immobile ... include mattress, mattresses overlay, and specialty beds. These devices ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
Breaking Medicine Technology:North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3
... /PRNewswire-FirstCall/ -- La Jolla,Pharmaceutical Company today announced updated ... of Riquent(R) (abetimus,sodium), its drug candidate for systemic ... the previous,conclusion that there is a definitive and ... and 900 mg doses of Riquent compared,with placebo ...
... Calando,Pharmaceuticals, a leading siRNA therapeutics company and ... announced the publication in the Proceedings of ... journal of the,NAS, of the first non-human ... Calando's lead siRNA therapeutic candidate that is ...
Cached Medicine Technology:La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5
(Date:6/2/2015)... June 02, 2015 Each year, Cosmetic ... Choice Beauty Awards. This year, the organization’s members – ... winner of the QVC® Beauty Quest Award at the ... Micro Emulsion (ME) Technology and 2-in-1 approach to skincare ... noting the brand’s loyal consumer and professional fan bases, ...
(Date:6/2/2015)... Join us for a new event in Westwood, New Jersey—the ... , who overcame her brain aneurysm during the summer of ... awareness and funds for brain aneurysm research. , Rhonda ... will be one less case of someone suffering from a ... the 1st Anniversary Awareness Walk in Honor of Rhonda ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Lynn Lester as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in business. ... professional women, boasting more than 700,000 members and over ... Lynn Lester with this prestigious award,” said NAPW President ...
(Date:6/1/2015)... 02, 2015 The National Association ... as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in safety, environment, health ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Lourinda with this important honor,” said ...
Breaking Medicine News(10 mins):Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2
... interdisciplinary team of researchers at Brigham and Women,s ... Sciences and Technology has demonstrated a better way to ... engineered nanoparticles that can inhibit a signaling pathway and ... area. Details of their work appear on April 20, ...
... Lincare Holdings Inc. (Nasdaq: LNCR ), a ... to patients in the home, today announced financial results for ... March 31, 2009, net revenues were $371.7 million, compared with ... 2008. Net income for the quarter ended March 31, ...
... April 20 Amgen (Nasdaq: AMGN ) today ... results on Thursday, April 23, 2009 after the close of ... conference call with the investment community at 2 p.m. Pacific ... Kevin Sharer, chairman and chief executive officer, and other members ...
... not have same impact, study finds , , MONDAY, April ... beverages can have a negative effect on the body,s ... increasing the risk of heart attack and stroke, a ... have that kind of impact, the study found. , ...
... SYK ) reported operating results for the quarter ended March ... , Net sales increased ... $1,601 million , Orthopaedic Implants ... reported) , MedSurg Equipment sales ...
... Environmental or therapeutic contact also led to poorer outcomes, ... Thyroid cancer patients who,ve previously been exposed to radiation ... patients, a new study finds. , Researchers at Mount ... who,d been exposed to radiation -- for example, in ...
Cached Medicine News:Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 5Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 6Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 7Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 2Health News:Stryker Operating Results for Quarter Ended March 31, 2009 3Health News:Stryker Operating Results for Quarter Ended March 31, 2009 4Health News:Stryker Operating Results for Quarter Ended March 31, 2009 5Health News:Stryker Operating Results for Quarter Ended March 31, 2009 6Health News:Stryker Operating Results for Quarter Ended March 31, 2009 7Health News:Stryker Operating Results for Quarter Ended March 31, 2009 8Health News:Radiation Exposure Linked to Aggressive Thyroid Cancers 2
... The Monarc Subfascial Hammock™ is ... female patients suffering from stress urinary ... by supporting the urethra during abdominal ... or laughing. Monarc's outside-to-in transobturator approach ...
... innovative architecture of the Uretex® ... and integrity for tension-free sling ... anchors securely to surrounding tissue ... alternate fixation devices, minimizing risk ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: